Eli Lilly increased its U.S. advertising expenditure on obesity and diabetes treatments to an estimated $214 million through the first nine months of 2025, up from just $85 million in the same period of 2024. The company allocated approximately $131 million to Zepbound—its weekly obesity injection—and $83 million to Mounjaro, its diabetes therapy. Despite trailing Novo Nordisk’s combined $487 million ad outlay on competing GLP-1 products, Lilly has captured roughly 60% of the U.S. obesity drug market, according to IQVIA data. Clinical results from a head-to-head trial released in late 2024 showed Zepbound patients achieved 47% greater mean weight loss versus users of the leading rival injection, reinforcing Lilly’s rapid prescription growth and market leadership.

Eli Lilly announced a $3.5 billion investment to build a new manufacturing facility in Lehigh Valley, Pennsylvania, its fourth U.S. plant under a broader plan to expand domestic capacity. Groundbreaking is slated for later this year, with operations expected by 2031. The site will produce next-generation obesity treatments, including the phase-III candidate retatrutide—which has delivered the highest weight-loss outcomes seen to date in late-stage trials—and future injectable and oral formulations. The project will create approximately 850 permanent roles (engineers, scientists, operations staff) and 2,000 construction jobs, bolstering Lilly’s strategy to avoid past supply shortages and support its leadership in the rapidly growing weight-management market.